Sign In
Buy ALX
$250.02
+3.19 (+1.29%)
At Close: Jun 03, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
08:00am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie
Alexander’s Completes Sale of Rego Park I
04:54pm, Thursday, 28'th May 2026
PARAMUS, N. J. , May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New
Alexander's Completes Sale of Rego Park I
04:54pm, Thursday, 28'th May 2026
PARAMUS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New Yo
The Most Hated High Yields On Wall Street
11:00am, Sunday, 17'th May 2026
Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!
First Look: Aramco profit jump, Nvidia-Corning deal, GM fined
07:37am, Monday, 11'th May 2026
Stock News Discount chains gain share: Budget-conscious consumers are flocking to discounters, with Aldi adding 17 million U.S. customers in 2025 and planning 1
ALX Oncology Q1 Earnings Call Highlights
04:07pm, Friday, 08'th May 2026
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-target
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Friday, 08'th May 2026
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable resp
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
Alexander's (ALX) Q1 FFO and Revenues Lag Estimates
10:46am, Monday, 04'th May 2026
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.6 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $4.06 per share a year ago.
A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34
06:21pm, Friday, 01'st May 2026
On May 01, 2026, Alexander's Inc (ALX) shares fell 3.0%, closing at $244.34. The stock has traded within a 52-week range of $201.28 to $260.84, reflecting some
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasda
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
11:30am, Wednesday, 29'th Apr 2026
PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May
Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
10:53am, Tuesday, 21'st Apr 2026
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended March 31, 2026 with the U.S. S
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
04:05pm, Friday, 17'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel ther
Longleaf Partners Small-Cap Fund Q1 2026 Portfolio Review
11:15am, Thursday, 16'th Apr 2026
Alcoholic beverage company Boston Beer was a contributor for the quarter as industry data improved compared to last year. Children's toy, media, and consumer products creator Mattel was a detractor in
